(Q30573058)

English

The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study

scientific article published on 8 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 June 2017

The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study (English)

1 reference

Europe PubMed Central

25 June 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

Valentina Fabiano

8

object named as

Valentina Fabiano

1 reference

Europe PubMed Central

25 June 2017

object named as

Elena Pariani

6

0 references

Antonella Amendola

object named as

Antonella Amendola

7

0 references

Paola Marchisio

object named as

Paola Marchisio

2

0 references

Gian Vincenzo Zuccotti

object named as

Gian Vincenzo Zuccotti

11

0 references

Susanna Esposito

object named as

Susanna Esposito

1

0 references

Sonia Bianchini

4

object named as

Sonia Bianchini

1 reference

Europe PubMed Central

25 June 2017

author name string

Valentina Montinaro

3

1 reference

Europe PubMed Central

25 June 2017

Gerrit Jan Weverling

5

1 reference

Europe PubMed Central

25 June 2017

Valentina Pivetti

9

1 reference

Europe PubMed Central

25 June 2017

Alessandro Zanetti

10

1 reference

Europe PubMed Central

25 June 2017

language of work or name

0 references

publication date

8 October 2012

1 reference

Europe PubMed Central

25 June 2017

1 reference

Europe PubMed Central

25 June 2017

30

1 reference

Europe PubMed Central

25 June 2017

49

1 reference

Europe PubMed Central

25 June 2017

7005-7012

1 reference

Europe PubMed Central

25 June 2017

Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old Children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Socioeconomic impact of influenza on healthy children and their families

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

The Japanese experience with vaccinating schoolchildren against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

The need for quadrivalent vaccine against seasonal influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Influenza vaccination coverage rate in children: reasons for a failure and how to go forward

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

High costs of influenza: Direct medical costs of influenza disease in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Influenza vaccination: the paediatric perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Potential burden of universal influenza vaccination of young children on visits to primary care practices

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

The feasibility of universal influenza vaccination for infants and toddlers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Recommendations for the use of influenza vaccine in pediatrics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Vaccination coverage rates in eleven European countries during two consecutive influenza seasons.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Safe vaccination of children with a virosomal adjuvanted influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Fever following administration of two inactivated influenza vaccines--a survey of parents of New Zealand infants and children 5 years of age and under

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

NSW annual report describing adverse events following immunisation, 2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.069

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.09.069

1 reference

Europe PubMed Central

25 June 2017

1 reference

Europe PubMed Central

25 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30573058&oldid=1739275779"